Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course treatment for drug-sensitive childhood pulmonary tuberculosis
ChiCTR2400089795Phase 4Not yet recruiting
- Sponsor
- Kunming Children's Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in Tuberculosis (TB) and pulmonary tuberculosis (TB) (2 arms), sponsored by Kunming Children's Hospital. Primary endpoints: Clinical symptom indicators, Imaging indicators and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2400089795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089795.